- Home
- ERAS vs STNG Comparison
ERAS vs STNG Comparison
Compare ERAS & STNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | STNG |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | Monaco |
| Employees | N/A | 24 |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERAS | STNG |
|---|---|---|
| Price | $19.18 | $76.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $14.25 | ★ $83.33 |
| AVG Volume (30 Days) | ★ 5.5M | 893.6K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.22% |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $42.20 |
| 52 Week High | $24.28 | $87.39 |
Technical Indicators
Market Signals| Indicator | ERAS | STNG |
|---|---|---|
| Relative Strength Index (RSI) | 73.23 | 50.23 |
| Support Level | $12.36 | $72.53 |
| Resistance Level | $24.28 | $78.29 |
| Average True Range (ATR) | 1.21 | 2.97 |
| MACD | 0.32 | 0.17 |
| Stochastic Oscillator | 90.66 | 52.38 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.